ClinicalTrials.gg
Enrolling by invitationNCT07208734Updated Oct 6, 2025

Personalized Brain Stimulation for Cognitive Impairment in Older Adults

An interventional study of Transcranial Alternating Current Stimulation (tACS) and AI-based Cognitive Training in Alzheimer s Disease, sponsored by Xuanwu Hospital, Beijing. Enrolling by invitation at 1 site in China. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2024, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing — 19 open to participants now, 20 under way, 1 of them phase 3. Alzheimer Disease · Xuanwu Hospital, Beijing.

Planned enrollment
2nd of 19
460 · median 40
Started
2024
with 2 others
No phase
13 of 26
8 open now
Primary completion
2027-06
later than 9 of 19 live
Registered
20th of 26
by date

Among the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, this one is the 2nd largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2024, is one of 13 with no phase, reaches primary completion later than 9 of the 19 other live ones, and was the 20th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

19 of the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

This study aims to develop and test new personalized treatments for older adults with cognitive impairment.

Project 1: Create a personalized cognitive training program using computer algorithms to match training tasks to individual needs. About 300 participants will join a randomized trial at hospitals and community health centers.

Project 2: Develop a personalized brain stimulation program (tACS) based on brain imaging and artificial intelligence. About 160 participants will be enrolled to test safety and effectiveness.

Project 3: Build a framework for ethical data management by reviewing international practices and consulting experts.

Together, these projects will provide evidence for safe, effective, and personalized care, while ensuring responsible use of research data.

Read the detailed description

This study is designed to improve the treatment and care of older adults with cognitive impairment through three related projects.

Project 1: Development of a personalized cognitive training program. Using advanced computer algorithms, we will match training tasks to each patient's needs across multiple cognitive domains. About 300 participants will be enrolled from hospitals and community health centers in two provinces to test the effectiveness of this program in a randomized controlled trial.

Project 2: Development of a personalized brain stimulation program. Based on brain imaging data and artificial intelligence models, we will create individualized transcranial alternating current stimulation (tACS) plans to deliver precise, safe, and effective stimulation. About 160 participants will be recruited from the same sites to evaluate safety and effectiveness in a randomized controlled trial.

Project 3: Development of a data governance and ethics framework. Building on the first two projects, we will review international literature and consult experts in ethics, geriatrics, neuroscience, and data governance to create a framework for managing multimodal data and ethical issues in cognitive impairment research.

Together, these projects aim to provide personalized, scientifically validated treatment strategies and ensure that research data are managed safely and ethically.

03

Conditions studied

  • Alzheimer s Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Inpatients or outpatients aged 50-90 years;
  2. Patients diagnosed with amnestic mild cognitive impairment (aMCI) due to AD or mild dementia due to AD, based on the 2018 NIA-AA clinical diagnostic criteria established by the National Institute on Aging and the Alzheimer's Association;
  3. Neuropsychological assessment showing scores between 18 and 26, and a CDR score of 0.5 or 1;
  4. Able to communicate fluently in Chinese (non-illiterate);
  5. For those currently receiving cholinesterase inhibitor therapy (e.g., donepezil or rivastigmine), the treatment dose must be stable, defined as a fixed dosage administered continuously for at least six weeks, with no adjustment of the medication regimen during the study period;
  6. Provision of written .

Exclusion criteria

Exclusion Criteria:

  1. Documented history of cerebrovascular stroke, with clear neurological deficits at onset and corresponding responsible lesions on neuroimaging;
  2. Moderate to severe white matter lesions (Fazekas score 3-6);
  3. Presence of any cause of consciousness disorder;
  4. Severe aphasia or motor disability that prevents completion of neuropsychological assessments;
  5. Current psychiatric disorders;
  6. History of alcohol dependence, drug addiction, traumatic brain injury, epilepsy, encephalitis, normal-pressure hydrocephalus, or other neurological disorders that may cause cognitive impairment;
  7. Systemic diseases that may contribute to mild cognitive impairment (e.g., hepatic or renal insufficiency, endocrine disorders, vitamin deficiencies);
  8. Considered unsuitable for participation by the investigators.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
460 participants (estimated)

Study arms

  • Experimental
    Transcranial Alternating Current Stimulation (tACS) or AI-based Cognitive Training

    Device: Transcranial Alternating Current Stimulation (tACS) · Other: AI-based Cognitive Training

  • Sham comparator
    Sham intervention

    Other: Sham intervention

Interventions

  • DeviceTranscranial Alternating Current Stimulation (tACS)

    Gamma TranscraniaThis intervention uses a personalized transcranial alternating current stimulation (tACS) protocol specifically designed for older adults with cognitive impairment. Unlike standard brain stimulation approaches, this protocol is individualized through artificial intelligence-based modeling of each participant's brain imaging data to optimize electric field distribution. The study will evaluate both safety and effectiveness in a multicenter randomized controlled trial.l Alternating Current Stimulation (tACS)

  • OtherAI-based Cognitive Training

    This intervention provides a personalized cognitive training program tailored to multiple cognitive domains. Using algorithm-based task matching, the system delivers training exercises adapted to each participant's cognitive profile. The program is designed to target memory, attention, executive function, and language, and will be validated through a multicenter randomized controlled trial.

  • OtherSham intervention

    The sham stimulation group will undergo the same setup procedures as the active tACS group, including electrode placement and device operation. However, no effective current will be delivered beyond an initial brief sensation, ensuring participants cannot distinguish sham from active stimulation. This allows blinding of participants and investigators to treatment allocation.

06

What researchers measure

Primary outcomes

  1. Moca score

    Time frame: Participants will undergo a screening period, a baseline period, an 8-week visit, and a 6-month visit (calculated from the first intervention) during the trial.

Secondary outcomes

  1. Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 11-items version).

    Time frame: Participants will undergo a screening period, a baseline period, an 8-week visit, and a 6-month visit (calculated from the first intervention) during the trial.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2027, 37 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 37 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartActual
May 1, 2024
Primary completionEst.
Jun 1, 2027
CompletionEst.
Nov 30, 2027
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07208734
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
May 1, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Oct 6, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion